SGLT-2 Inhibitor Use Not Linked to Increased Risk for UTI Events
Findings seen in propensity-matched cohorts versus receipt of DPP-4 inhibitors or GLP-1 agonists
Diabetes Mellitus Type 2
Reducing HF Hospitalization Risk: Antidiabetic Drug Classes Compared
The authors searched for randomized placebo-controlled trials (December 1, 2008 to November 24, 2017) involving 3 pharmacologic classes of antidiabetic medications to compare the effects of these agents on the risk of hospitalization for HF in T2DM patients.
FDA: Cases of Rare Gangrene of Genital Area Tied to Diabetes Drug Class
The infection developed within several months of the patients starting SGLT2 therapy and the drug was discontinued in most cases. All patients required surgery and there was 1 reported death.
Oral Semaglutide Appears Safe, Effective in T2D Patients With Renal Impairment
PIONEER 5 (N=324) was a randomized, double-blind, placebo-controlled, parallel-group, 26-week trial that evaluated the safety and efficacy of oral semaglutide 14mg vs placebo in patients with type 2 diabetes and moderate renal impairment (eGFR 30 to 59mL/min/1.73m2) inadequately controlled with metformin, sulfonylurea alone or in combination with metformin, or basal insulin alone or in combination with metformin.
FDA Approves FreeStyle Libre 14 Day Flash Glucose Monitoring System
The new Flash Glucose Monitoring System enables patients to wear the sensor for up to 14 days compared with the existing FreeStyle Libre System that was approved for 10-day wear.
New Data Support Long-Term Cardiovascular Safety of Linagliptin in T2D
Results showed the overall safety profile of linagliptin in study patients, including adults with kidney disease, was consistent with previous data.
FDA Clears Omnipod DASH System for Diabetes Management
The Omnipod DASH system consists of a discreet, tubeless, waterproof Pod which is worn on the body, and the Personal Diabetes Manager (PDM), a handheld wireless device used to control the Pod.
SGLT2 Inhibitors Canagliflozin, Dapagliflozin Compared in Real-World Study
Researchers performed a retrospective cohort study by identifying patients from the Optum Clinformatics database who were initiated on canagliflozin 300mg or dapagliflozin 100mg from January 1, 2014 to September 30, 2016.
Canagliflozin May Improve Renal Outcomes in Patients With T2D
The renal protective benefit was seen in patients with both reduced (eGFR <60mL/min/1.73m2) and preserved (eGFR ≥60mL/min/1.73m2) renal function.
Bydureon Approved for Use With Basal Insulin for Uncontrolled T2D
The DURATION-7 study examined the effect of Bydureon or placebo as add-on therapy to insulin glargine, with or without metformin, in adults with T2D.
